By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Siemens Healthcare Diagnostics today announced two deals to develop companion diagnostics for candidate drugs currently in clinical trials.

One deal with ViiV Healthcare focuses on ViiV's Celsentri/Selzentry (maraviroc) AIDS therapy. The other with Tocagen is targeted at that firm's gene therapy for treating primary brain cancer.

Financial details were not disclosed for either deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.